McGill Integrated Cancer Program Institute for Applied Cancer Science
The McGill Integrated Cancer Program Institute highlights achievements in cancer research continuum, focusing on basic research, genomic technologies, and precision oncology for improved clinical outcomes. The program aims to tackle cancer grand challenges and drive innovation in cancer treatment. Collaborative efforts across McGill University contribute to optimizing patient care and advancing cancer research.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
McGill Integrated Cancer Program Institute for Applied Cancer Science Achievements and Next Steps to Tackle Cancer Grand Challenges An update for Faculty of Medicine Retreat December 2017
Cancer Research Continuum Basic research is the foundation on which the cancer research continuum is built.
Cancer Research Continuum Basic research is the foundation on which the cancer research continuum is built. Genomic and other omic based technologies WHY DO PATIENTS FAIL TO RESPOND TO THERAPIES? NEW KNOWLEDGE = NEW THERAPEUTIC STRATEGIES
Precision Oncology Cancer diagnosis and treatment are changing Use of molecular-based profiling of individual patient s tumor: Improve overall clinical outcomes Optimize patient- treatment matching Avoid predictably ineffective, toxic and costly treatments
Precision Oncology Cancer diagnosis and treatment are changing Use of molecular-based profiling of individual patient s tumor: Improve overall clinical outcomes Optimize patient- treatment matching Avoid predictably ineffective, toxic and costly treatments molecular pathology
Precision Oncology Cancer diagnosis and treatment are changing Use of molecular-based profiling of individual patient s tumor: Improve overall clinical outcomes Optimize patient- treatment matching Avoid predictably ineffective, toxic and costly treatments molecular pathology
Precision Oncology Cancer diagnosis and treatment are changing Use of molecular-based profiling of individual patient s tumor: Improve overall clinical outcomes Optimize patient- treatment matching Avoid predictably ineffective, toxic and costly treatments Driven by and is a driver for cancer research and innovation Is McGill well positioned to maximise opportunities?
The Challenge Increased Collaboration across McGill McGill: World-class cancer researchers; however . Relatively small teams Geographically and administratively dispersed Resources are fragmented and not centrally planned No McGill wide brand, identity or shared vision Lack unification or integration of research efforts -clinical-basic-translational A history of competition between units rather than collaboration Interdisciplinarity Bridging Silos Biologist Bioinformatics Clinician Engineer Statistician Epidemiology Systems Biology
The challenge- Funding climate is changing Enhanced: Multidisciplinary large scale team grants with established track records Problem: Increased application pressure National Cancer Consortia Group Grants (ie. TFRI) (ie. SU2C; NCE) International Initiatives Reduced success rates from traditional funding sources (ie. CIHR, CCS, CRS) (ie. Moonshot US; Grand Challenges UK) Requires a fundamental shift in the way we conduct cancer research
Integrated Research Approach- Cancer Grand Challenge unmet clinical need Hard-to-Treat Cancers Biospecimen Cancer Biobank & Data Repository Molecular Profiling & Personalized Treatment Models of Cancers Clinical Trials Efficacy of Precision Medicine IMPROVE OUTCOMES FOR HARD-TO-TREAT CANCERS Discover New Targets Validate Targets Develop Therapies Understand Biology 10 Program Overview
Current Challenge the old model Surgical Clinical and Radiological Practice Tissue and Data Banks Cancer patient population Knowledge Translation and Patient Impact Basic and Translational Research >8,500 Partnerships with Industry for Target Validation and Drug Development Interdisciplinary Research Non FoM Genomics/omics Big Data Sharing Platform Integration 11 11
Cancer Grand Challenge Research Approach unmet clinical need Surgical Clinical and Radiological Practice Tissue and Data Banks Cancer patient population Knowledge Translation and Patient Impact Basic and Translational Research >8,500 Partnerships with Industry for Target Validation and Drug Development Interdisciplinary Research Non FoM Genomics/omics Big Data Sharing Platform Integration 12
Cancer Integrated Network - Grand Challenge Research Goals To leverage the power of fundamental, translational and clinical research for the detection, prevention, long-term management and cure of cancers. Integrated Approach build close integration of clinical practice with research harmonize data warehouse-outcomes-across sites increase and harness clinical trials for discovery targeted tissue and liquid biopsy repositories for discovery and validation develop multidisciplinary and interdisciplinary teams apply integrated systems approaches to understanding of disease - patient centric harness the power of multi-omic big data exploit clinical data through AI innovations-radiomics
What would a Grand Challenge Approach Accomplish 1 2 3 4 5 Precision Therapies Therapy Resistance Prevention Diagnosis Metastasis Invasive Approaches Improved Detection Improved Non Precision Oncology Life Style Choices Predisposition Novel Therapies New therapies Genetic Imaging dependencies Tumor/stroma Small molecule inhibitors prevention Liquid Biopsies Host immune Antibody-based therapies Metastatic niche Biomarkers Immune therapies Point of care devices Care Devices Tumor evolution Novel Point of Metabolic therapies Epigenetic therapies
Who would be partners at McGill? 1 2 3 4 5 Precision Therapies Therapy Resistance Prevention Diagnosis Metastasis McGill Initiative in Computational Medicine BioX McGill Interdisciplinary Initiative in Infection and Immunity (MI4) McGill Stem Cell and Regenerative Medicine Nanotechnology Innovative devices Disruptive technologies Disruptive biologicals Inflammation Immune modulation Microbiome Cancer stem cells Resistance Technologies (IPS)
Improve Outcomes to Cancer Therapies PRIORITIZED THEMES CANCER CHALLENGES STATE OF THE ART HOSPITALS New Cancer Treatments Novel Cancer Vulnerabilities - Metabolic dependencies of cancers - Tumour immune evasion - Synthetic lethality New Tumor Targets - Drug repurposing - New drugs High Burden Cancers High Fatality Cancers Real World Evidence Resistance to treatment and metastases IMPLEMENTATION STRATEGIES Annotated Tumour Tissue Banks Cutting Edge Technologies -Live Tumour Tissue Core (PDX) -Omics Core Facilities -Immune Phenotyping Core -Synthetic lethality Core Cancer Genomics-Bioinformatics Expertise-New Recruitment Cancer Genomics-Bioinformatics Technology Development Forge New Partnerships (clinicians, engineers) Develop New Funding Opportunities
What would an Integrated Cancer Network accomplish? Foster Foster interdisciplinary multidisciplinary and interdisciplinary multidisciplinary and interinstitutional research: interinstitutional research: Training programs: enhance existing MICRTP partner with existing departments and programs to develop co-training models to serve as nodes Seed grants: small one-time funding opportunities to bring together new teams to tackle priority areas Shared platforms and harmonization: personnel support, resource sharing and strategic planning to maximize platform usefulness and lifespan Secure large scale funding: early identification, project management and identification of co-funding for large scale initiatives (MESI, NCE, MESI, Terry Fox)
Training the Next Generation Recruit the Best and Brightest in all Disciplines World-Class Mentorship Nationally and Internationally recognized clinicians and the Training researchers Cancer Cancer training training stream stream Generation next Ground-Breaking Cutting-Edge Technologies Training through integrated core platforms Interdisciplinary Research Projects at the forefront of basic and clinically applicable cancer research
Funding Opportunities Ongoing Terry Fox Comprehensive Cancer Centre Network (PMH, BCCA) - Montreal Cancer Consortium (JGH, MUHC, CHUM, HMR, GCRC, IRIC) - harnessing Melanoma Network immunotherapy clinical trials - $4M/2yr Pilot Project Terry Fox Research Institute National Networks - EPIC (Pancreatic) (PYA) Multiple Myeloma Minist re de l Economie, Science et Innovation (MESI) (LOI Dec 2017) - MCC (MUHC, CHUM, JGH, HMR, GCRC, IRIC, LDI) $20M/4 yrs high burden and high fatality increase clinical trial recruitment - Using AI to Build Radiogenomics-Based Predictors for Response to Precision Therapies in Cancer (MUHC, JGH, CHUM) Oncopole EMC2 Multi-institutional teams against cancer - At least 3 institutions/research centres/departments, 2 Universities - LOI: Nov. 2017 - 1.5M/3yrs Expect to fund 4 grants-opportunities to integrate McGill
Fundraising Need Partnership Approach McGill University Capital Campaign - funds raised can support Units at McGill that are contributing to a Cancer Grand Challenge facilities for generation of data from clinical material Motivated Donors - want to contribute to large research initiatives that include partnerships between McGill and affiliated Hospitals Hospital Foundations - funds raised can support clinical trials and tissue banking efforts focused on a Cancer Grand Challenge Other opportunities? MESI, Terry Fox, NCE, SPOR Requires a strategy to highlight that funds are being raised jointly to tackle large scale projects that span the fundamental/clinical/translational continuum of cancer research
Ongoing work and Next Steps Ongoing work and Next Steps Cancer Summit Spring 2018 Strategic plan development Establish working groups from all pillars Develop a governance plan Define science, priority programs and vision Determine our needs and draft a budget Identify the role for donor support in a comprehensive funding plan Establish next steps Build our research teams and programs Generate performance metrics and comparator data Develop provincial, national and international partnerships
